The Antinociceptive Role of Nrf2 in Neuropathic Pain: From Mechanisms to Clinical Perspectives
Pharmaceutics · 15.08.2024 · 16 (8) · 1068
DOI: 10.3390/pharmaceutics16081068 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 15.08.2024. Verfasst von Kestutis Petrikonis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Lithuanian University of Health Sciences, Eivenių Str. 2, LT-50009 Kaunas, Lithuania. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 213 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Lithuania (LMTLT).
Abstract (Originalsprache)
Neuropathic pain, a chronic condition resulting from nerve injury or dysfunction, presents significant therapeutic challenges and is closely associated with oxidative stress and inflammation, both of which can lead to mitochondrial dysfunction. The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, a critical cellular defense mechanism against oxidative stress, has emerged as a promising target for neuropathic pain management. Nrf2 modulators enhance the expression of antioxidant and cytoprotective genes, thereby reducing oxidative damage, inflammation, and mitochondrial impairment. This review explores the antinociceptive effects of Nrf2, highlighting how pharmacological agents and natural compounds may be used as potential therapeutic strategies against neuropathic pain. Although preclinical studies demonstrate significant pain reduction and improved nerve function through Nrf2 activation, several clinical challenges need to be addressed. However, emerging clinical evidence suggests potential benefits of Nrf2 modulators in several conditions, such as diabetic neuropathy and multiple sclerosis. Future research should focus on further elucidating the molecular role of Nrf2 in neuropathic pain to optimize its modulation efficacy and maximize clinical utility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Lithuanian University of Health Sciences, Eivenių Str. 2, LT-50009 Kaunas, Lithuania.
- Department of Drug Technology and Social Pharmacy, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50161 Kaunas, Lithuania.
- Institute of Pharmaceutical Technologies, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50161 Kaunas, Lithuania.
- Opusmedica Persons, Care & Research-NPO, 29121 Piacenza, Italy.
- Department of Medicine and Health Sciences "V. Tiberio", University of Molise, 86100 Campobasso, Italy.
- Department of Physiology and Pharmacology "Vittorio Erspamer", La Sapienza University, 00185 Rome, Italy.
ORCID-Profile: Jurga Bernatoniene, Dalia M Kopustinskiene, Roberto Casale, Sergio Davinelli, Luciano Saso
Förderung
- Research Council of Lithuania (LMTLT)
Zitieren
APA
Petrikonis, K., Bernatoniene, J., Kopustinskiene, D. M., Casale, R., Davinelli, S., & Saso, L. (2024). The Antinociceptive Role of Nrf2 in Neuropathic Pain: From Mechanisms to Clinical Perspectives. Pharmaceutics, 16(8), 1068. https://doi.org/10.3390/pharmaceutics16081068
Vancouver
Petrikonis K, Bernatoniene J, Kopustinskiene DM, Casale R, Davinelli S, Saso L. The Antinociceptive Role of Nrf2 in Neuropathic Pain: From Mechanisms to Clinical Perspectives. Pharmaceutics. 2024;16(8):1068. doi:10.3390/pharmaceutics16081068
BibTeX
@article{Petrikonis2024,
author = {Petrikonis, Kestutis and Bernatoniene, Jurga and Kopustinskiene, Dalia M and Casale, Roberto and Davinelli, Sergio and Saso, Luciano},
title = {The Antinociceptive Role of Nrf2 in Neuropathic Pain: From Mechanisms to Clinical Perspectives},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {8},
pages = {1068},
doi = {10.3390/pharmaceutics16081068}
}
EUVIMED